| 5.89 0.78 (15.26%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.25 |
1-year : | 8.47 |
| Resists | First : | 6.21 |
Second : | 7.25 |
| Pivot price | 5.29 |
|||
| Supports | First : | 5.19 |
Second : | 4.55 |
| MAs | MA(5) : | 5.21 |
MA(20) : | 5.21 |
| MA(100) : | 4.02 |
MA(250) : | 3.3 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1  |
| %K %D | K(14,3) : | 38.7 |
D(3) : | 26.7 |
| RSI | RSI(14): 62.5 |
|||
| 52-week | High : | 6.84 | Low : | 1.42 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BDTX ] has closed Bollinger Bands are 16.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.96 - 5.98 | 5.98 - 6.01 |
| Low: | 5.11 - 5.13 | 5.13 - 5.15 |
| Close: | 5.85 - 5.89 | 5.89 - 5.94 |
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Thu, 25 Apr 2024
Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect? - Zacks Investment Research
Wed, 24 Apr 2024
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO ... - GlobeNewswire
Thu, 11 Apr 2024
Black Diamond Therapeutics Announces Changes to Board of Directors - GlobeNewswire
Sun, 07 Apr 2024
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in ... - GlobeNewswire
Wed, 03 Apr 2024
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Tue, 12 Mar 2024
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 93.5 (%) |
| Shares Short | 2,040 (K) |
| Shares Short P.Month | 1,780 (K) |
| EPS | -1.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34.4 % |
| Return on Equity (ttm) | -71 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -67 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -3.14 |
| PEG Ratio | 0 |
| Price to Book value | 2.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|